Instil Bio Inc (TIL)
31.76
+0.14
(+0.46%)
USD |
NASDAQ |
Nov 14, 12:35
Instil Bio Research and Development Expense (Quarterly): 2.921M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 2.921M |
| March 31, 2024 | 7.256M |
| December 31, 2023 | 1.983M |
| September 30, 2023 | 8.492M |
| June 30, 2023 | 8.459M |
| March 31, 2023 | 20.67M |
| December 31, 2022 | 20.72M |
| September 30, 2022 | 39.66M |
| June 30, 2022 | 41.50M |
| Date | Value |
|---|---|
| March 31, 2022 | 39.17M |
| December 31, 2021 | 42.58M |
| September 30, 2021 | 29.06M |
| June 30, 2021 | 21.19M |
| March 31, 2021 | 14.42M |
| December 31, 2020 | 10.25M |
| September 30, 2020 | 4.908M |
| June 30, 2020 | 2.237M |
| March 31, 2020 | 2.007M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.983M
Minimum
Dec 2023
42.58M
Maximum
Dec 2021
17.64M
Average
12.34M
Median
Research and Development Expense (Quarterly) Benchmarks
| Merck & Co Inc | 5.862B |
| Elite Pharmaceuticals Inc | 2.164M |
| BioCardia Inc | 0.80M |
| Zevra Therapeutics Inc | 10.52M |
| NovaBay Pharmaceuticals Inc | 0.009M |